Ella Jones, PhD
|School||UCSF School of Medicine|
|Address||2200 Post St., MZ Bldg C|
San Francisco CA 94115
|American Chemical Society||1986||Undergraduate Award in Analytical Chemistry|
|American Chemical Society||1987||Student Award|
|University of California, Davis||1987
||1991||Non-resident Tuition Fellowship|
|University of California, Davis||1991||Outstanding Graduate Student Nominee|
|University of Oxford||1991
||1993||Assoicated Member of Balliol College|
|Mallinckrodt Medical, Inc.||1994||2 Outstanding Patent Awards|
|Monsanto Chemical Company||1997
||2001||Chair of the Monsanto Technical Community, Phosphorus Chapter|
|Solutia, Inc.||2001||Chair of the Solution Science and Engineering Network|
|Department of Defense, Breast Cancer||2009||Peer Reviewer|
|National Institute of Health, Challenge grants||2009||Peer Reviewer|
|Department of Defense, Breast Cancer||2010||Peer Reviewer|
| National Institute of Health, NIBIB Training SEP||2010||Peer Reviewer|
| National Institute of Health, NIBIB Quantum Projects||2010||Peer Reviewer|
|World Molecular Imaging Congress Meeting||2013||Section Chair and Moderator|
|World Molecular Imaging Congress Meeting||2013||Poster Award Recipient|
| Department of Defense, Breast Cancer||2015||Peer Reviewer|
Cancer development is a multi-step process with well-defined pathological characteristics. It undergoes sequential stages from normal tissues to proliferative benign lesions and finally carcinomas and invasive carcinomas. These stages can be broadly defined as premalignancy, malignancy and metastasis. Study of the underlying cellular and molecular signaling pathways at different stages of cancer not only will advance our understanding of the disease itself, it will also help us to develop new tools for early detection, personalized treatment and ultimately strategies of disease prevention. Dr. Jones' research is to fully integrate cell biology, protein engineering and synthetic chemistry to develop new reporter systems for in vivo imaging of biomarkers that are important to all stages of cancer development. Her interests include in vivo characterization of variant human mammary epithelial cells (vHMECs) in breast premalignancy, targeted imaging of malignant prostate cancer with prostate specific membrane antigen (PSMA) inhibitors and molecular imaging of metastatic lymph nodes in breast cancer using dendrimer based protease sensing probes. As an enabling technology, nanoparticles in forms of dendritic polymer, liposomes and quantum dots are also being explored to advance cancer imaging in Jones' laboratory.
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.